Corvus Pharmaceuticals, Inc.: diluted weighted-average shares
Diluted weighted-average shares for Corvus Pharmaceuticals, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Corvus Pharmaceuticals, Inc. financial histories
What this measure means
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
Exact concept: us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 79,742,685 | shares | 2026-03-12 | 10-K · 0001104659-26-027047 |
| 2024-01-01 | 2024-12-31 | 60,985,165 | shares | 2026-03-12 | 10-K · 0001104659-26-027047 |
| 2023-01-01 | 2023-12-31 | 48,025,274 | shares | 2026-03-12 | 10-K · 0001104659-26-027047 |
| 2022-01-01 | 2022-12-31 | 46,553,511 | shares | 2025-03-25 | 10-K · 0001558370-25-003621 |
| 2021-01-01 | 2021-12-31 | 41,854,110 | shares | 2024-03-19 | 10-K · 0001558370-24-003567 |
| 2020-01-01 | 2020-12-31 | 29,478,878 | shares | 2023-03-28 | 10-K · 0001558370-23-004792 |
| 2019-01-01 | 2019-12-31 | 29,349,810 | shares | 2022-03-10 | 10-K · 0001558370-22-003281 |
Related financial histories
- Corvus Pharmaceuticals, Inc.: total assets
- Corvus Pharmaceuticals, Inc.: total liabilities
- Corvus Pharmaceuticals, Inc.: stockholders equity
- Corvus Pharmaceuticals, Inc.: cash and cash equivalents
- Corvus Pharmaceuticals, Inc.: net income or loss
- Corvus Pharmaceuticals, Inc.: operating cash flow
- Corvus Pharmaceuticals, Inc.: capital expenditure payments
- Corvus Pharmaceuticals, Inc.: financing cash flow
- Corvus Pharmaceuticals, Inc.: investing cash flow
- Corvus Pharmaceuticals, Inc.: retained earnings or deficit
- Corvus Pharmaceuticals, Inc.: basic weighted-average shares
- Corvus Pharmaceuticals, Inc.: basic earnings per share
- Corvus Pharmaceuticals, Inc.: diluted earnings per share
- Corvus Pharmaceuticals, Inc.: net property, plant and equipment
- Corvus Pharmaceuticals, Inc.: share-based compensation expense
- Corvus Pharmaceuticals, Inc.: operating income or loss
- Corvus Pharmaceuticals, Inc.: current assets
- Corvus Pharmaceuticals, Inc.: current liabilities
- Corvus Pharmaceuticals, Inc.: current accounts payable
- Corvus Pharmaceuticals, Inc.: net current accounts receivable
- Corvus Pharmaceuticals, Inc.: operating expenses
- Corvus Pharmaceuticals, Inc.: research and development expense
Inspect the source
- Entity
- Corvus Pharmaceuticals, Inc. / CIK 0001626971
- Captured
- 2026-09-21T17:21:55.204Z
- SEC response SHA-256
efaff8dff6bd932c7ac2851cff10f1e493b250491e3b60ca38d6cd7189bac6f4
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001626971.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))